azacitidine has been researched along with Constipation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarado, Y; Andreeff, M; Borthakur, G; Bose, P; Chien, KS; Cortes, JE; Daver, NG; DiNardo, CD; Dong, XQ; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Kim, K; Klingner-Winton, C; Montalban-Bravo, G; Naqvi, K; Nogueras-Gonzalez, GM; Pierce, SA; Sheppard, KB; Soltysiak, KA | 1 |
| Al-Ali, HK; Cross, M; Hoppe, G; Jaekel, N; Junghanss, C; Krahl, R; Maschmeyer, G; Niederwieser, D | 1 |
2 trial(s) available for azacitidine and Constipation
| Article | Year |
|---|---|
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites; Arthralgia; Azacitidine; Constipation; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Pneumonia; Programmed Cell Death 1 Receptor; Progression-Free Survival; Risk | 2021 |
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Constipation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2012 |